Dr. Manuel Hidalgo
After a national search spanning several years, the Weill Department of Medicine (WDOM) is pleased to announce that Dr. Manuel Hidalgo will serve as Chief of the Division of Hematology and Medical Oncology effective June 1, 2019. Recruited from Harvard Medical School, Dr. Hidalgo is currently the Theodore W. and Evelyn G. Berenson Professor of Medicine at Harvard Medical School and serves as Chief of the Division of Hematology/Oncology, as well as the Clinical Director of the Rosenberg Clinical Cancer Center, at Beth Israel Deaconess Medical Center in Boston. He also serves as the Deputy Associate Director for Clinical Sciences at the Dana-Farber/Harvard Cancer Center in Boston.
A premier investigator in the areas of translational and clinical drug development, Dr. Hidalgo has been at the helm of the early clinical development of more than 50 new anticancer agents. Among these agents, he led erlotinib, temsirolimus, and nab-paclitaxel development which are now FDA approved for the treatment of cancer. Nationally and internationally recognized, Dr. Hidalgo is an authority on pancreatic cancer and has published more than 220 articles in the top tier peer-reviewed journals. His immediate goal is to incorporate immune treatment approaches, both in preclinical models and clinical studies, for pancreatic cancer. Dr. Hidalgo’s research funding includes The National Cancer Institute, and he was the recipient of a European Research Council advanced grant. His interests in translational and clinical anticancer drug development began at The University of Texas Health Science Center at San Antonio (UTHSCSA) in San Antonio, Texas, followed by work at Johns Hopkins where he pioneered the development of PDX models (mouse avatar) models for metastatic PDAC.
Dr. Hidalgo has participated in multiple teaching activities in oncology, including pre-graduate teaching in medical school, clinical teaching of fellows and residents, supervision of Ph.D. students, and mentoring of fellows and junior faculty. He is one of the Directors of the Vail ASCO-AACR course in clinical cancer research, has delivered multiple educational presentations around the world, and was the director of a Master’s Degree program in Clinical Investigations in Oncology.
Dr. Hidalgo obtained his M.D. from the University of Navarra in Pamplona, Spain, and a Ph.D. in Infectious Diseases and Cancer from the University Autonoma of Madrid, Spain. He also holds a M.Sc. in Medicine from Harvard University. He completed his residency training at the Hospital “12 de Octubre” in Madrid and a fellowship in Medical Oncology at UTHSCSA. He has served as an Associate Professor at Johns Hopkins and is presently a Professor of Medicine at Harvard. Since 2015, he has served as Chief of the Division of Hematology/Oncology at Beth Israel Deaconess Medical Center-Boston, Boston.
The WDOM welcomes Dr. Hidalgo and looks forward to his leadership in furthering new horizons throughout our tripartite mission of clinical care, research, and education.
With deepest appreciation, the WDOM thanks Dr. David M. Nanus for his outstanding service as Chief of the Division of Hematology and Medical Oncology. Throughout his tenure, Dr. Nanus has furthered numerous advances in hematology and medical oncology while exemplifying the highest level of excellence as a clinician, educator, and investigator. He joined the academic faculty of Weill Cornell Medicine in 1998 and served as Co-Chief of his division, along with Dr. Barbara Hempstead, from 2004 until 2012. In 2012, when Dr. Hempstead stepped down, Dr. Nanus continued as Division Chief. In 2016, he became the Director of the NewYork-Presbyterian’s and Weill Cornell Medicine’s Healthcare Services’ Cancer Program. A member of the American Society for Clinical Investigation and the American Association of Physicians, Dr. Nanus is the Mark W. Pasmantier Professor of Hematology & Oncology in Medicine and the Associate Director of Clinical Services for the Meyer Cancer Center. The WDOM looks forward to his continued leadership throughout the NYPH/WCM network.